AssetMark Inc’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.6M | Buy |
139,443
+2,905
| +2% | +$383K | 0.03% | 385 |
|
|
2026
Q1 | $19M | Sell |
136,538
-8,145
| -6% | -$1.14M | 0.04% | 340 |
|
|
2025
Q4 | $17.8M | Sell |
144,683
-11,435
| -7% | -$1.39M | 0.04% | 353 |
|
|
2025
Q3 | $17.3M | Buy |
156,118
+28,701
| +23% | +$3.26M | 0.04% | 336 |
|
|
2025
Q2 | $14.1M | Buy |
127,417
+70,327
| +123% | +$7.48M | 0.03% | 338 |
|
|
2025
Q1 | $6.4M | Sell |
57,090
-239,780
| -81% | -$24.7M | 0.02% | 455 |
|
|
2024
Q4 | $27.4M | Sell |
296,870
-1,880,494
| -86% | -$169M | 0.07% | 198 |
|
|
2024
Q3 | $183M | Buy |
2,177,364
+109,118
| +5% | +$8.33M | 0.52% | 39 |
|
|
2024
Q2 | $142M | Sell |
2,068,246
-346,599
| -14% | -$23.1M | 0.44% | 44 |
|
|
2024
Q1 | $177M | Buy |
2,414,845
+17,200
| +0.7% | +$1.32M | 0.58% | 41 |
|
|
2023
Q4 | $194M | Sell |
2,397,645
-9,671
| -0.4% | -$753K | 0.7% | 35 |
|
|
2023
Q3 | $180M | Buy |
2,407,316
+271,971
| +13% | +$20.9M | 0.72% | 33 |
|
|
2023
Q2 | $165M | Buy |
2,135,345
+856,228
| +67% | +$68.3M | 0.65% | 39 |
|
|
2023
Q1 | $106M | Buy |
1,279,117
+32,720
| +3% | +$2.71M | 0.44% | 55 |
|
|
2022
Q4 | $107M | Sell |
1,246,397
-43,155
| -3% | -$3.42M | 0.46% | 52 |
|
|
2022
Q3 | $79.6M | Buy |
1,289,552
+67,859
| +6% | +$4.28M | 0.37% | 63 |
|
|
2022
Q2 | $75.5M | Sell |
1,221,693
-11,659
| -0.9% | -$722K | 0.34% | 66 |
|
|
2022
Q1 | $73.3M | Buy |
1,233,352
+638,450
| +107% | +$40.8M | 0.31% | 77 |
|
|
2021
Q4 | $43.2M | Buy |
594,902
+588,627
| +9,381% | +$40.5M | 0.18% | 130 |
|
|
2021
Q3 | $438K | Sell |
6,275
-7,607
| -55% | -$534K | ﹤0.01% | 474 |
|
|
2021
Q2 | $956K | Sell |
13,882
-4,869
| -26% | -$325K | ﹤0.01% | 388 |
|
|
2021
Q1 | $1.21M | Sell |
18,751
-20,797
| -53% | -$1.34M | 0.01% | 349 |
|
|
2020
Q4 | $2.3M | Sell |
39,548
-17,360
| -31% | -$1.05M | 0.01% | 296 |
|
|
2020
Q3 | $3.6M | Sell |
56,908
-27,698
| -33% | -$1.92M | 0.02% | 265 |
|
|
2020
Q2 | $6.51M | Buy |
84,606
+49,971
| +144% | +$3.83M | 0.05% | 219 |
|
|
2020
Q1 | $2.59M | Sell |
34,635
-730
| -2% | -$50.4K | 0.02% | 262 |
|
|
2019
Q4 | $2.3M | Sell |
35,365
-456,723
| -93% | -$29.7M | 0.02% | 304 |
|
|
2019
Q3 | $31.2M | Buy |
492,088
+91,512
| +23% | +$5.98M | 0.26% | 99 |
|
|
2019
Q2 | $27.1M | Sell |
400,576
-214,548
| -35% | -$14.1M | 0.22% | 104 |
|
|
2019
Q1 | $40M | Buy |
615,124
+57,456
| +10% | +$3.82M | 0.36% | 74 |
|
|
2018
Q4 | $34.9M | Buy |
557,668
+96,531
| +21% | +$6.75M | 0.34% | 75 |
|
|
2018
Q3 | $35.6M | Buy |
461,137
+12,520
| +3% | +$946K | 0.32% | 74 |
|
|
2018
Q2 | $31.8M | Buy |
448,617
+16,610
| +4% | +$1.17M | 0.31% | 70 |
|
|
2018
Q1 | $32.6M | Sell |
432,007
-27,870
| -6% | -$2.22M | 0.34% | 67 |
|
|
2017
Q4 | $32.9M | Buy |
459,877
+12,579
| +3% | +$955K | 0.34% | 75 |
|
|
2017
Q3 | $36.2M | Buy |
447,298
+368,182
| +465% | +$28.2M | 0.41% | 65 |
|
|
2017
Q2 | $5.6M | Buy |
79,116
+33,743
| +74% | +$2.25M | 0.07% | 181 |
|
|
2017
Q1 | $3.08M | Buy |
45,373
+35,881
| +378% | +$2.52M | 0.04% | 215 |
|
|
2016
Q4 | $679K | Buy |
9,492
+113
| +1% | +$8.4K | 0.01% | 298 |
|
|
2016
Q3 | $742K | Sell |
9,379
-8,987
| -49% | -$730K | 0.01% | 275 |
|
|
2016
Q2 | $1.53M | Sell |
18,366
-1,958
| -10% | -$174K | 0.03% | 236 |
|
|
2016
Q1 | $1.87M | Buy |
20,324
+348
| +2% | +$31.4K | 0.03% | 220 |
|
|
2015
Q4 | $2.02M | Buy |
19,976
+12,186
| +156% | +$1.27M | 0.04% | 213 |
|
|
2015
Q3 | $765K | Buy |
7,790
+7,578
| +3,575% | +$842K | 0.02% | 264 |
|
|
2015
Q2 | $25K | Buy |
+212
| New | +$23.2K | ﹤0.01% | 449 |
|
|
2015
Q1 | – | Sell |
-15,239
| Closed | -$1.44M | – | 478 |
|
|
2014
Q4 | $1.44M | Buy |
+15,239
| New | +$1.58M | 0.03% | 244 |
|
Other funds holding GILD
AssetMark Inc's GILD Position: Q2 2026 in Review
AssetMark Inc increased its Gilead Sciences (GILD) stake by 2.1% in Q2 2026, buying an estimated $383K and bringing the position to 139,443 shares worth $17.6M. The position accounts for 0.03% of the portfolio, ranked #385.
AssetMark Inc first reported a position in GILD in Q4 2014 and has held it in 46 quarters since. The position peaked at $194M in Q4 2023. 1,032 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- AssetMark Inc held 139,443 shares of Gilead Sciences worth $17.6M as of Q2 2026.
- AssetMark Inc bought 2,905 Gilead Sciences shares in Q2 2026, an estimated $383K.
- Gilead Sciences made up 0.03% of AssetMark Inc's portfolio in Q2 2026, its #385 holding.
- AssetMark Inc first reported a position in Gilead Sciences in Q4 2014 and has held it in 46 quarters since.
- AssetMark Inc's Gilead Sciences position peaked at $194M in Q4 2023.
- 1,032 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.